Core Viewpoint - Novartis has announced an agreement to acquire Regulus Therapeutics, focusing on developing microRNA therapeutics for autosomal dominant polycystic kidney disease (ADPKD) with the lead asset farabursen, which is positioned as a potential first-in-class treatment [1][2]. Transaction Details - The acquisition involves a tender offer for all outstanding shares of Regulus common stock at USD 7 per share, with an additional contingent value right (CVR) of up to USD 7 per share based on regulatory milestones [3][8]. - The transaction is expected to close in the second half of 2025, pending customary closing conditions and regulatory approvals [5][8]. Clinical Development - Farabursen is an investigational microRNA inhibitor targeting miR-17, designed to reduce cyst growth and kidney size while delaying disease progression in ADPKD [2][8]. - Regulus recently completed a Phase 1b clinical trial for farabursen, showing promising efficacy and safety results, including impacts on urinary polycystin and height-adjusted total kidney volume [2][8]. Novartis' Commitment to Renal Health - Novartis has a long-standing commitment to renal health, with recent FDA approvals for treatments addressing significant unmet needs in kidney diseases, including IgA nephropathy and C3 glomerulopathy [6].

Core Viewpoint - Regulus Therapeutics Inc. is actively participating in the 2025 Oppenheimer Innovation on the Island Biotech Summit, highlighting its focus on innovative medicines targeting microRNAs [1]. Company Overview - Regulus Therapeutics Inc. is a biopharmaceutical company listed on Nasdaq (RGLS) that specializes in the discovery and development of medicines aimed at microRNAs [3]. - The company has developed a robust pipeline supported by a strong intellectual property portfolio in the microRNA sector [3]. - Regulus is headquartered in San Diego, California [3]. Event Participation - Jay Hagan, the CEO of Regulus, will present at the summit on April 9th, 2025, at 11:32 a.m. ET [1]. - The live event and its replay will be accessible through the investor relations section of the company's website for 90 days post-presentation [2].

Core Insights - Regulus Therapeutics announced positive topline results from the fourth cohort of its Phase 1b MAD study of farabursen for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD) [2][4] - The study demonstrated a significant halting of kidney volume growth in patients receiving a 300 mg fixed dose of farabursen over four months [1][4] - The company is on track to initiate a Phase 3 pivotal trial in Q3 2025, with a focus on a 12-month endpoint for kidney volume change [2][6] Study Details - The Phase 1b MAD study was a double-blind, placebo-controlled trial assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of farabursen in adult ADPKD patients [3] - The study included three weight-based dose levels and one fixed dose level, with primary endpoints focused on urinary PC1 and PC2 changes, and an exploratory examination of htTKV growth rate [3][4] - In the fourth cohort, 26 subjects received 300 mg of farabursen bi-weekly for three months, showing consistent mechanistic responses and halting htTKV growth [4][5] Efficacy and Safety - Patients treated with farabursen showed a mean htTKV growth rate of 0.05%, compared to 2.58% in placebo subjects, indicating a significant reduction in kidney volume growth [5] - Urinary levels of PC1 and PC2 increased significantly, correlating with the observed effects on kidney volume [5] - Farabursen demonstrated a favorable safety and tolerability profile, consistent with earlier cohorts, with no serious adverse events reported [5][9] Future Plans - The company has confirmed alignment with the FDA regarding the Phase 3 trial design, which includes a 12-month htTKV endpoint for Accelerated Approval and a 24-month eGFR endpoint for Full Approval [6][9] - Regulus aims to advance farabursen as a potential treatment option for ADPKD, addressing a significant unmet medical need [6][10] Background on ADPKD - ADPKD is a common genetic disorder characterized by the development of multiple cysts in the kidneys, leading to end-stage renal disease in approximately 50% of patients by age 60 [8] - The disease affects around 160,000 individuals in the U.S., with a global prevalence estimated between 4 to 7 million [8]

Core Insights - Regulus Therapeutics Inc. reported positive topline results from an interim analysis of the fourth cohort in the Phase 1b multiple-ascending dose clinical trial of farabursen for treating autosomal dominant polycystic kidney disease (ADPKD) [1][2] - The company has reached an agreement with the FDA on key components for a Phase 3 single pivotal trial, which may allow for Accelerated Approval based on a 12-month htTKV endpoint [2][5] Program Updates - The interim analysis involved 14 subjects from the fourth cohort, showing a favorable safety and tolerability profile, with evidence of a mechanistic dose response and a suggested reduction in kidney volume growth rate [2][3] - In the fourth cohort, 26 subjects received a fixed dose of 300 mg of farabursen every other week for three months, with results indicating similar effects on polycystin biomarkers compared to previous cohorts [3][4] - The Phase 1b MAD study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of farabursen in adult patients with ADPKD [4] Financial Results - As of December 31, 2024, the company had $75.8 million in cash, cash equivalents, and short-term investments, with an expected cash runway extending into early 2026 [6] - Research and development expenses for Q4 2024 were $9.7 million, compared to $5.8 million in Q4 2023, while total R&D expenses for the year were $35.4 million, up from $21.2 million in 2023 [6] - General and administrative expenses for Q4 2024 were $4.1 million, compared to $2.5 million in Q4 2023, with total G&A expenses for the year at $14.7 million, up from $10.0 million in 2023 [7] - The net loss for Q4 2024 was $12.8 million, or $0.20 per share, compared to a net loss of $8.1 million, or $0.40 per share, in Q4 2023 [8][14] About ADPKD - Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder leading to end-stage renal disease, characterized by the development of multiple cysts in the kidneys [9] - Approximately 160,000 individuals are diagnosed with ADPKD in the U.S., with a global prevalence estimated between 4 to 7 million [9] About Farabursen - Farabursen (RGLS8429) is a novel oligonucleotide designed to inhibit miR-17 and target the kidney, showing improvements in kidney function and size in preclinical models [10] - The Phase 1 studies have demonstrated that farabursen is well-tolerated with no serious adverse events reported [10] About Regulus - Regulus Therapeutics Inc. focuses on discovering and developing innovative medicines targeting microRNAs, with a strong intellectual property portfolio in the microRNA field [11]